Pds biotech completes first stage of enrollment in checkpoint inhibitor refractory arm of phase 2 clinical trial in advanced hpv16 positive head and neck cancer

Versatile-002 phase 2 study investigating pds0101 in combination with merck's keytruda® (pembrolizumab) in both checkpoint inhibitor refractory and checkpoint inhibitor naÏve patients versatile-002 phase 2 study investigating pds0101 in combination with merck's keytruda® (pembrolizumab) in both checkpoint inhibitor refractory and checkpoint inhibitor naÏve patients
PDSB Ratings Summary
PDSB Quant Ranking